These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
290 related articles for article (PubMed ID: 23568282)
21. A Phase II study of weekly irinotecan and capecitabine in patients with previously treated non-small cell lung cancer. Han JY; Lee DH; Kim HY; Kim EA; Lee JJ; Ju SY; Shin EH; Lee JS Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5909-14. PubMed ID: 14676114 [TBL] [Abstract][Full Text] [Related]
22. Phase II study of weekly irinotecan and cisplatin for refractory or recurrent non-small cell lung cancer. Takiguchi Y; Moriya T; Asaka-Amano Y; Kawashima T; Kurosu K; Tada Y; Nagao K; Kuriyama T Lung Cancer; 2007 Nov; 58(2):253-9. PubMed ID: 17658654 [TBL] [Abstract][Full Text] [Related]
23. Irinotecan and vinorelbine in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. A phase II study of the Hellenic Cooperative Oncology Group. Pectasides D; Fountzilas G; Rigopoulos A; Bountouroglou NG; Koutras A; Glotsos J; Onyenadum A; Makatsoris T; Kalofonos HP Anticancer Res; 2002; 22(6B):3501-6. PubMed ID: 12552946 [TBL] [Abstract][Full Text] [Related]
24. Phase II study of irinotecan and carboplatin for advanced non-small cell lung cancer. Takeda K; Takifuji N; Uejima H; Yoshimura N; Terakawa K; Negoro S Lung Cancer; 2002 Dec; 38(3):303-8. PubMed ID: 12445753 [TBL] [Abstract][Full Text] [Related]
25. A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens. Kosmas C; Tsavaris N; Syrigos K; Koutras A; Tsakonas G; Makatsoris T; Mylonakis N; Karabelis A; Stathopoulos GP; Kalofonos HP Cancer Chemother Pharmacol; 2007 Jan; 59(1):51-9. PubMed ID: 16622691 [TBL] [Abstract][Full Text] [Related]
26. Vinorelbine in combination with carboplatin followed by single-agent consolidation therapy for unresectable localized or metastatic non-small-cell lung carcinomas. Alici S; Coskun U; Alkis N; Sevinc A; Dane F; Gumus M; Ozkan M; Kaya AO; Celenkoglu G; Buyukberber S; Altunbas M; Benekli M; Asian Pac J Cancer Prev; 2009; 10(6):1051-5. PubMed ID: 20192582 [TBL] [Abstract][Full Text] [Related]
27. Phase II study of carboplatin combined with weekly docetaxel in patients with advanced non-small cell lung cancer. Jiang L; Wang DY; Zhu ZH; Tang LF; Hou XH; Zhao HD; Xie Z; Wang DF Cancer Chemother Pharmacol; 2010 Aug; 66(3):449-53. PubMed ID: 19937029 [TBL] [Abstract][Full Text] [Related]
28. Irinotecan and carboplatin in metastatic or recurrent NSCLC: an update. Read W; McLeod H; Govindan R Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):15-7. PubMed ID: 15685828 [TBL] [Abstract][Full Text] [Related]
29. Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experience. Langer CJ; Leighton JC; Comis RL; O'Dwyer PJ; McAleer CA; Bonjo CA; Engstrom PF; Litwin S; Johnson S; Ozols RF Semin Oncol; 1995 Aug; 22(4 Suppl 9):18-29. PubMed ID: 7544025 [TBL] [Abstract][Full Text] [Related]
30. Phase II study of carboplatin and weekly paclitaxel combination chemotherapy in advanced non-small cell lung cancer: a Kansai Clinical Oncology Group study. Hirabayashi M; Endoh K; Teramachi M; Okuda M; Yamaguchi K; Fukuda K; Tokuhisa H; Kagioka H; Nakai N; Nakade M Lung Cancer; 2004 Jun; 44(3):355-62. PubMed ID: 15140549 [TBL] [Abstract][Full Text] [Related]
31. Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small-cell lung cancer. Naka N; Kawahara M; Okishio K; Hosoe S; Ogawara M; Atagi S; Takemoto Y; Ueno K; Kawaguchi T; Tsuchiyama T; Furuse K Lung Cancer; 2002 Sep; 37(3):319-23. PubMed ID: 12234702 [TBL] [Abstract][Full Text] [Related]
32. Cisplatin in combination with metronomic vinorelbine as front-line treatment in advanced non-small cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG). Katsaounis P; Kotsakis A; Agelaki S; Kontopodis E; Agelidou A; Kentepozidis N; Vamvakas L; Christopoulou A; Karachaliou N; Hatzidaki D; Georgoulias V Cancer Chemother Pharmacol; 2015 Apr; 75(4):821-7. PubMed ID: 25702051 [TBL] [Abstract][Full Text] [Related]
33. Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin in patients with chemo-naïve extensive-stage small-cell lung cancer: North Japan Lung Cancer Study Group (NJLCG) 0901. Morikawa N; Inoue A; Sugawara S; Maemondo M; Harada T; Harada M; Fujita Y; Katoh T; Yokouchi H; Watanabe H; Usui K; Suzuki T; Sakakibara-Konishi J; Nagai H; Kanbe M; Nukiwa T Lung Cancer; 2017 Sep; 111():38-42. PubMed ID: 28838395 [TBL] [Abstract][Full Text] [Related]
34. Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017. Borghaei H; Langer CJ; Millenson M; Ruth KJ; Litwin S; Tuttle H; Seldomridge JS; Rovito M; Mintzer D; Cohen R; Treat J J Thorac Oncol; 2008 Nov; 3(11):1286-92. PubMed ID: 18978564 [TBL] [Abstract][Full Text] [Related]
35. Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial. Paccagnella A; Favaretto A; Oniga F; Festi G; Lauro S; Morabito A; Ossana L; Sartore F; DePoli F; Fiorentino MV Cancer; 1996 Oct; 78(8):1701-7. PubMed ID: 8859183 [TBL] [Abstract][Full Text] [Related]
36. A weekly combination of carboplatin and irinotecan for previously untreated extensive disease small-cell lung cancer, results of a minimum follow-up of 3 years: a multi-center Phase II trial JMTO LC02-02. Okishio K; Mio T; Kawahara M; Yoshioka H; Yanagihara K; Daimon T; Furuse K Jpn J Clin Oncol; 2012 May; 42(5):387-93. PubMed ID: 22430871 [TBL] [Abstract][Full Text] [Related]
37. Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma. Reck M; Macha HN; Del Barco S; Cornes P; Vaissière N; Morand M; Riggi M; Abratt R Lung Cancer; 2009 Jun; 64(3):319-25. PubMed ID: 19095327 [TBL] [Abstract][Full Text] [Related]
38. Phase I study of radical thoracic radiation, weekly irinotecan, and cisplatin in locally advanced non-small cell lung carcinoma. Langer CJ; Somer R; Litwin S; Feigenberg S; Movsas B; Maiale C; Sherman E; Millenson M; Nicoloau N; Huang C; Treat J J Thorac Oncol; 2007 Mar; 2(3):203-9. PubMed ID: 17410043 [TBL] [Abstract][Full Text] [Related]
39. Front-line treatment of advanced non-small cell lung cancer with irinotecan and docetaxel: a multicentre phase II study. Ziotopoulos P; Androulakis N; Mylonaki E; Chandrinos V; Zachariadis E; Boukovinas I; Agelidou A; Kentepozidis N; Ignatiadis M; Vossos A; Georgoulias V; Lung Cancer; 2005 Oct; 50(1):115-22. PubMed ID: 15993981 [TBL] [Abstract][Full Text] [Related]
40. A phase II study of biweekly paclitaxel and carboplatin in elderly patients with advanced non-small cell lung cancer. Soejima K; Naoki K; Ishioka K; Nakamura M; Nakatani M; Kawada I; Watanabe H; Nakachi I; Yasuda H; Satomi R; Nakayama S; Yoda S; Ikemura S; Terai H; Sato T; Ohgino K; Arai D; Tani T; Kuroda A; Nishino M; Betsuyaku T Cancer Chemother Pharmacol; 2015 Mar; 75(3):513-9. PubMed ID: 25563719 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]